Oppenheimer Asset Management Inc. Lowers Stock Holdings in Glaukos Co. (NYSE:GKOS)

Oppenheimer Asset Management Inc. lowered its holdings in shares of Glaukos Co. (NYSE:GKOSGet Rating) by 18.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,829 shares of the medical instruments supplier’s stock after selling 3,581 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Glaukos were worth $719,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Captrust Financial Advisors boosted its position in Glaukos by 119.5% during the first quarter. Captrust Financial Advisors now owns 1,484 shares of the medical instruments supplier’s stock worth $86,000 after purchasing an additional 808 shares in the last quarter. Hardy Reed LLC acquired a new position in shares of Glaukos during the first quarter valued at approximately $90,000. Nisa Investment Advisors LLC raised its holdings in shares of Glaukos by 16.1% during the first quarter. Nisa Investment Advisors LLC now owns 3,170 shares of the medical instruments supplier’s stock valued at $183,000 after acquiring an additional 440 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Glaukos during the first quarter valued at approximately $208,000. Finally, Quantum Private Wealth LLC acquired a new position in shares of Glaukos during the first quarter valued at approximately $222,000. Hedge funds and other institutional investors own 93.09% of the company’s stock.

Glaukos Price Performance

GKOS stock opened at $50.70 on Wednesday. The business has a fifty day moving average of $53.91 and a two-hundred day moving average of $49.08. The company has a quick ratio of 6.84, a current ratio of 7.40 and a debt-to-equity ratio of 0.64. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -26.68 and a beta of 1.26. Glaukos Co. has a 52-week low of $33.33 and a 52-week high of $64.49.

Glaukos (NYSE:GKOSGet Rating) last posted its earnings results on Wednesday, November 2nd. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.08. The company had revenue of $71.27 million during the quarter, compared to analysts’ expectations of $67.88 million. Glaukos had a negative return on equity of 16.16% and a negative net margin of 31.45%. As a group, research analysts anticipate that Glaukos Co. will post -2.19 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a report on Thursday, November 3rd. Needham & Company LLC reduced their target price on Glaukos from $66.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, November 3rd. Citigroup increased their target price on Glaukos from $54.00 to $57.00 in a report on Wednesday, October 5th. JPMorgan Chase & Co. cut their price target on Glaukos from $52.00 to $48.00 and set an “underweight” rating for the company in a report on Thursday, November 3rd. Finally, Piper Sandler increased their price target on Glaukos from $55.00 to $60.00 and gave the company a “neutral” rating in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $60.13.

About Glaukos

(Get Rating)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Recommended Stories

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.